The current financial score of Pulmatrix Inc is 6.80. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Pulmatrix Inc is 6.61. Its current P/E ratio is -1.37, which is -71.42% below the recent high of -0.39 and -179.08% above the recent low of -3.83.
No earnings forecast score is currently available for Pulmatrix Inc. The Biotechnology & Medical Research industry's average is 8.11.
The current price momentum score of Pulmatrix Inc is 4.88. Currently, the stock price is trading between the resistance level at 1.85 and the support level at 1.46, making it suitable for range-bound swing trading.
The current institutional shareholding score of Pulmatrix Inc is 3.00. The latest institutional shareholding proportion is 10.12%, representing a quarter-over-quarter increase of 8.89%. The largest institutional shareholder is James Simons, holding a total of 122.70K shares, representing 0.00% of shares outstanding, with 73.86% decrease in holdings.
The current risk assessment score of Pulmatrix Inc is 2.43. The company's beta value is 1.95. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.